Rhythm Pharmaceuticals Inc.
RYTMHeld by 10 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying10 funds opened new positions. Next phase3 readout (Setmelanotide): Mar 2025. Short interest: 11.8% of float.
Held by 10 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying10 funds opened new positions. Next phase3 readout (Setmelanotide): Mar 2025. Short interest: 11.8% of float.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)
10 specialist funds hold RYTM with a Phase 2 in 111 days for Setmelanotide (Prader-Willi Syndrome, Obesity, Hyperphagia)
+5 more upcoming catalysts
Position history (shares)
RYTM – Rock Springs adds $16.5M. Rock Springs, a healthcare specialist running a concentrated book, added 256,488 shares to reach a $90.9M position in Rhythm Pharmaceuticals, signaling increased conviction in setmelanotide's pipeline across rare genetic obesity indications ahead of near-term readouts — notably a Phase 3 in hypothalamic obesity (expected March 2025) and Phase 3 in genetic obesity (December 2025). The melanocortin pathway franchise is the core thesis, with additional data on RM-718 (PWS/hypothalamic obesity, Phase 2 Part A) and bivamelagon (hypothalamic obesity, Phase 2) extending the runway into 2027-2028.
7 quarters
Nov 14, 2025
$1.6B
6 funds
Feb 17, 2026
$1.8B
6 funds
May 15, 2026
$1.5B
7 funds
May 29, 2026
$218.8M
1 fund
-10% total institutional value over 21 quarters
Short Shares
8.01M
Change
-3.4%
Days to Cover
12.8
% of Float
11.8%
Settlement
Jun 15, 2026
Short interest over 10 periods
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.
# Investment Summary: RYTM Setmelanotide Formulation Research **Clinical/Commercial Relevance:** This research addresses pharmaceutical manufacturing optimization for setmelanotide, Rhythm's approved rare disease treatment, by investigating pH-dependent drug loading efficiency into PLGA microspheres—a long-acting injectable delivery platform. Successfully engineering improved formulations could enhance patient convenience through extended dosing intervals and potentially expand the addressable market by improving tolerability and compliance in POMC/PCSK1/PDYN pathway obesity patients. **Investor Takeaway:** The work suggests Rhythm is actively developing next-generation delivery systems beyond the current oral formulation, which could represent a meaningful commercial differentiator and provide lifecycle extension opportunities as patent expiration timelines approach.
# Investment Summary: Setmelanotide in Craniopharyngioma-Associated Obesity This real-world study demonstrates setmelanotide's safety and effectiveness in pediatric craniopharyngioma patients with severe obesity, expanding clinical evidence beyond the rare genetic obesity indications for which RYTM received FDA approval. The data supports potential label expansion or off-label adoption in this secondary indication, though craniopharyngioma-related obesity represents a modest market opportunity compared to RYTM's core genetic obesity franchise. Investors should monitor whether positive real-world findings translate into expanded clinical trials or reimbursement coverage, as this could modestly broaden the addressable patient population but is unlikely to materially impact revenue guidance without formal regulatory or payer actions.
# Investment Summary: Setmelanotide Economic Evaluations I cannot provide this summary because the article you've referenced (published April 20, 2026) is from the future and does not yet exist. As an analyst, I can only review published, accessible research. **If you have access to an actual setmelanotide economic evaluation study**, I'd be happy to analyze it for RYTM investors. Key metrics I would typically evaluate include: - Cost-effectiveness ratios and payer acceptance thresholds - Real-world budget impact across geographies - Reimbursement barriers or opportunities - Patient access implications for rare genetic obesity Please provide the actual article, and I can deliver the clinical/commercial analysis you need for investment decision-making.
# Setmelanotide in Bardet-Biedl Syndrome – Investment Summary **Clinical Finding:** This case report documents setmelanotide's therapeutic activity in a Bardet-Biedl syndrome patient, expanding evidence for RYTM's lead asset beyond its FDA-approved POMC pathway obesity indication to a rare genetic disorder with significant unmet need. **Investment Implication:** The data supports potential label expansion or new indication development for setmelanotide in rare genetic obesity disorders, which could diversify RYTM's revenue streams and extend patent protection, though the single case report provides limited evidence for near-term commercial impact compared to larger controlled trials.
# Investment Summary: RYTM Setmelanotide Case Report **Clinical Finding:** A 2-year-old patient with leptin receptor (LEPR) deficiency achieved meaningful improvements in hyperphagia and obesity markers following setmelanotide treatment, extending clinical evidence to the youngest age group studied for this indication. **Investment Implications:** This case report strengthens the commercial rationale for RYTM's rare genetic obesity franchise by demonstrating early-onset efficacy and supporting potential label expansion into pediatric populations, which could broaden the addressable market beyond current approved indications (POMC, PCSK1, PRKAG2 deficiency). However, a single pediatric case report carries limited regulatory weight; broader pediatric trial data would be necessary to materially impact revenue forecasts or reimbursement positioning.
Start free trialfor share counts, dollar values & AI analysis
98 more position changes — start your free trial to see dollar values and AI analysis for all of them.
Track specialist biotech funds, insider signals, and AI analysis
Start 14-Day Free TrialGet free weekly alerts on fund moves and catalysts: